X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PANACEA BIOTECH - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PANACEA BIOTECH IPCA LABS/
PANACEA BIOTECH
 
P/E (TTM) x 45.0 171.2 26.3% View Chart
P/BV x 3.5 3.8 90.8% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-17
PANACEA BIOTECH
Mar-14
IPCA LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs643149 432.4%   
Low Rs50382 610.9%   
Sales per share (Unadj.) Rs254.484.1 302.4%  
Earnings per share (Unadj.) Rs16.1-18.3 -87.8%  
Cash flow per share (Unadj.) Rs29.8-6.7 -444.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.683.7 232.4%  
Shares outstanding (eoy) m126.2061.25 206.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.4 164.1%   
Avg P/E ratio x35.7-6.3 -565.1%  
P/CF ratio (eoy) x19.2-17.2 -111.6%  
Price / Book Value ratio x2.91.4 213.4%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3007,074 1,022.0%   
No. of employees `00013.32.8 483.7%   
Total wages/salary Rs m6,9601,449 480.3%   
Avg. sales/employee Rs Th2,413.51,874.1 128.8%   
Avg. wages/employee Rs Th523.2527.0 99.3%   
Avg. net profit/employee Rs Th152.4-407.7 -37.4%   
INCOME DATA
Net Sales Rs m32,1065,154 623.0%  
Other income Rs m226100 226.2%   
Total revenues Rs m32,3325,254 615.4%   
Gross profit Rs m4,448-766 -580.4%  
Depreciation Rs m1,730711 243.2%   
Interest Rs m2411,503 16.0%   
Profit before tax Rs m2,703-2,881 -93.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m67517 4,019.0%   
Profit after tax Rs m2,028-1,121 -180.9%  
Gross profit margin %13.9-14.9 -93.2%  
Effective tax rate %25.0-0.6 -4,282.7%   
Net profit margin %6.3-21.8 -29.0%  
BALANCE SHEET DATA
Current assets Rs m17,3403,810 455.1%   
Current liabilities Rs m9,5598,365 114.3%   
Net working cap to sales %24.2-88.4 -27.4%  
Current ratio x1.80.5 398.2%  
Inventory Days Days100156 64.4%  
Debtors Days Days5767 84.6%  
Net fixed assets Rs m20,77914,480 143.5%   
Share capital Rs m25261 411.7%   
"Free" reserves Rs m24,499903 2,712.7%   
Net worth Rs m24,5535,127 478.9%   
Long term debt Rs m3,5175,832 60.3%   
Total assets Rs m39,59519,433 203.7%  
Interest coverage x12.2-0.9 -1,334.0%   
Debt to equity ratio x0.11.1 12.6%  
Sales to assets ratio x0.80.3 305.8%   
Return on assets %5.72.0 291.7%  
Return on equity %8.3-21.9 -37.8%  
Return on capital %10.53.6 288.4%  
Exports to sales %48.624.5 198.4%   
Imports to sales %14.210.2 139.8%   
Exports (fob) Rs m15,6171,264 1,235.7%   
Imports (cif) Rs m4,571525 871.0%   
Fx inflow Rs m15,6171,539 1,014.6%   
Fx outflow Rs m5,828942 618.7%   
Net fx Rs m9,790597 1,639.3%   
CASH FLOW
From Operations Rs m2,764599 461.3%  
From Investments Rs m-1,432-438 326.9%  
From Financial Activity Rs m-1,591-303 525.9%  
Net Cashflow Rs m-259-141 183.2%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.6 1,900.0%  
FIIs % 25.3 1.3 1,946.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.6 73.7%  
Shareholders   36,892 10,259 359.6%  
Pledged promoter(s) holding % 2.1 35.1 6.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS